News & Research - HBM Partners AG

Important legal information

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

Lupin Acquires Symbiomix Therapeutics LLC (51 KB)
11.10.2017
Download
AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis (769 KB)
10.10.2017
Download
Harmony Biosciences Acquires US Rights to Pitolisant from Bioprojet; Raises $270 Million in Equity Financing (129 KB)
5.10.2017
Download
ObsEva Completes Patient Recruitment for Phase 3 IVF Trial (291 KB)
6.9.2017
Download
ARMO BioSciences Raises $67 Million in a Series C‐1 Financing (134 KB)
29.8.2017
Download
Vascular Dynamics Announces FDA Approval to Initiate CALM 2 Trial for MobiusHD® System for the Treatment of Resistant Hypertension (346 KB)
15.8.2017
Download
Homology Medicines Raises $83.5 Million Series B Round to Advance Gene Therapy _Gene Editing (54 KB)
1.8.2017
Download
Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA (153 KB)
27.7.2017
Download
HBM & Existing Investors Double Down on 1mg with a $15M Series C Financing (365 KB)
26.7.2017
Download
Complexa Raises $62 Million in Series C Financing to Test CXA-10 in Two Orphan Disease Proof-of-Concept Trials (415 KB)
26.7.2017
Download

<1 2 345 6 >

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more
Der Kampf gegen das Vergessen (561 KB)
4.6.2018
Download Read more
Die Zuversicht für den Biotech-Sektor wächst (328 KB)
18.11.2017
Download Read more
Novartis setzt auf Nuklearmedizin (106 KB)
31.10.2017
Download Read more
Novartis's neue Wette im Krebsgeschäft (1502 KB)
31.10.2017
Download Read more
Trends und Chancen für den Anleger (840 KB)
1.9.2017
Download Read more
Strong Vital Signs in Biotech Innovation (4732 KB)
1.9.2017
Download Read more
Fokus auf Innovation (118 KB)
1.9.2017
Download Read more
Wie Anleger erfolgreich in Biotech investieren (535 KB)
27.5.2017
Download Read more
Trump und Big Pharma sind eine Hassliebe (166 KB)
4.2.2017
Download Read more
Fondsspezialitäten und ihre Macher (138 KB)
1.2.2017
Download Read more
Wie Biotech-Aktien auf Donald Trump reagieren (683 KB)
26.1.2017
Download Read more
Trump lässt Pharmaanleger erschauern (165 KB)
12.1.2017
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (190 KB)
12.9.2016
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

HBM Pharma / Biotech M&A Report 2019 (1263 KB)
Download
Pharma / Biotech M&A Transactions 2005-2018 (106 KB)
Download

Credits

Sitemap

Important legal information

Lupin Acquires Symbiomix Therapeutics LLC (51 KB)

AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis (769 KB)

Harmony Biosciences Acquires US Rights to Pitolisant from Bioprojet; Raises $270 Million in Equity Financing (129 KB)

ObsEva Completes Patient Recruitment for Phase 3 IVF Trial (291 KB)

ARMO BioSciences Raises $67 Million in a Series C‐1 Financing (134 KB)

Vascular Dynamics Announces FDA Approval to Initiate CALM 2 Trial for MobiusHD® System for the Treatment of Resistant Hypertension (346 KB)

Homology Medicines Raises $83.5 Million Series B Round to Advance Gene Therapy _Gene Editing (54 KB)

Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA (153 KB)

HBM & Existing Investors Double Down on 1mg with a $15M Series C Financing (365 KB)

Complexa Raises $62 Million in Series C Financing to Test CXA-10 in Two Orphan Disease Proof-of-Concept Trials (415 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Der Kampf gegen das Vergessen (561 KB)

Die Zuversicht für den Biotech-Sektor wächst (328 KB)

Novartis setzt auf Nuklearmedizin (106 KB)

Novartis's neue Wette im Krebsgeschäft (1502 KB)

Trends und Chancen für den Anleger (840 KB)

Strong Vital Signs in Biotech Innovation (4732 KB)

Fokus auf Innovation (118 KB)

Wie Anleger erfolgreich in Biotech investieren (535 KB)

Trump und Big Pharma sind eine Hassliebe (166 KB)

Fondsspezialitäten und ihre Macher (138 KB)

Wie Biotech-Aktien auf Donald Trump reagieren (683 KB)

Trump lässt Pharmaanleger erschauern (165 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (190 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

HBM Pharma / Biotech M&A Report 2019 (1263 KB)

Pharma / Biotech M&A Transactions 2005-2018 (106 KB)